High Purity 99% Compound 7P CAS 1890208-58-8 CAS NO.1890208-58-8

Hubei Langyou International Trading Co., Ltd is a renowned pharmaceutical manufacturer. We specializing in the production of research and development of pharmaceutical intermediates, this kind of products with high quality price concessions, welcomed the new and old customers advisory purchase, companies invest large fund and brain research fine chemical r&d department,biochemical,  pharmaceutical and intermediate products to meet the demand of the market. High level research team,advanced equipment and good scientific atmosphere ensure the quality .

1.Reasonable and competitive price. Provide the best and professional service.Provide the best and professional service is our purpose.

2. Reliable shipping way.Door to door service, guarantee 100% delivery for you.

We have our own shipping agent in each country,we have special lines to your country, you no need do anything.

Will finish all the customs clearance at our side, customers are without any customs issues,door to door delivery.

3.To below countries, we are very  familiar and regular.

UK,USA,Canada,Russia,Ukraine,Kazakhstan,Belarus,Germany,Poland,Sweden,the Netherlands, Australia,Spain,Mexico,Poland  and so on. All are without problems.

Compound 7P  cas：1890208-58-8

Compound 7P

MF： C22H23N3O5S

MW： 441.5

CAS： 1890208-58-8

Compound 7p was developed as one in series of compounds with the aim of identifying dual-acting thromboxane receptor
antagonist/synthase inhibitors . In fact compound 7p shows selectivity for prostaglandin I2 synthase (PTGIS , CYP8A1) over thromboxane synthase (CYP5A1).Axon regeneration after injury in the central nervous system is hampered in part because if an age-dependent decline in the intrinsic axon growth potential , and one of the strategies to stimulate axon growth in injured neurons involves pharmacological manipulation of implicated signaling pathways.
 

Function
Axon regeneration after injury in the central nervous system is hampered in part because if an age-dependent decline in the intrinsic axon growth potential , and one of the strategies to stimulate axon growth in injured neurons involves pharmacological manipulation of implicated signaling pathways.here we report phenotypic cell-based screen of chemical libraries and structure-activity-guided optimization that resulted in the identification of compound 7p which promotes neurite outgrowth of cultured primary neurons derived from the hippocampus, cerebral cortex, and retina. in an animal model of optic nerve injury, compound 7p was shown to induce growth of gap-43 positive axons, indicating that the in vitro neurite outgrowth activity of compound 7p translates into stimulation of axon regeneration in vivo.further optimization of compound 7p and elucidation of the mechanisms by which it elicits axon regeneration in vivo will provide a rational basis for future efforts to enhance treatment strategies.
Appliction
Compound 7p was developed as one in series of compounds with the aim of identifying dual-acting thromboxane receptor antagonist/synthase inhibitors . In fact compound 7p shows selectivity for prostaglandin I2 synthase (PTGIS , CYP8A1) over thromboxane synthase (CYP5A1) .

Axon regeneration after injury in the central nervous system is hampered in part because if an age-dependent decline in the intrinsic axon growth potential, and one of the strategies to stimulate axon growth in injured neurons involves pharmacological manipulation of implicated signaling pathways.